Biologic therapy in Crohn's disease: State of the art

Current Opinion in Gastroenterology

Volumn 24, Issue 4, 2008, Pages 475-481

  Jones, Jennifer ^a   Panaccione, Remo ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Anti tumor necrosis factor therapy; Biological therapy; Crohn's disease; Treatment

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CELL ADHESION MOLECULE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DRUG ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 12P40; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 7; NATALIZUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR;

BIOLOGICAL THERAPY; CELL MIGRATION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; CYTOKINE PRODUCTION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE REACTION; LEUKOCYTE; MONOTHERAPY; MULTIPLE SCLEROSIS; PHARMACOLOGICAL BLOCKING; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; QUALITY ADJUSTED LIFE YEAR; RECEPTOR GENE; REMISSION; REVIEW; SIDE EFFECT; TH17 CELL; UNSPECIFIED SIDE EFFECT;

BIOLOGICAL THERAPY; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOLOGIC FACTORS;

EID: 67649756681     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3283043596     Document Type: Review

References (40)

1. Shanahan F. Host-flora interactions in inflammatory bowel disease. Inflamm Bowel Dis 2004; 10 (Suppl 1):S16-S24.
2. Lichtenstein GR, Bala M, Han C, et al. Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis 2002; 8:237-243.
3. Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis: a long-term follow-up of 1116 patients. Dig Dis Sci 1993; 38:1137-1146.
4. Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995; 30:699-706.
5. Munkholm P. Crohn's disease: occurrence, course and prognosis: an epidemiologic cohort-study. Dan Med Bull 1997; 44:287-302.
6. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99:956-963.
7. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005; 54:237-241.
8. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350:876-885.
9. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359:1541 -1549.
10. Targan SR, Hanauer SB, van DeventerSJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337:1029-1035.
11. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4:621 -630.
12. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004; 53:849-853.
13. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56:1232-1239.
14. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human antitumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130:323-333.
15. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146:829-838.
16. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132:52-65.
17. Colombel JF, Schwartz MK, et al. Sustainability of adalimumab in fistula healing and response: 2-year data from CHARM and 12 month open-label extension follow-up study. Am J Gastroenterol 2007; 102:S497.
18. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357:228-238.
19. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357:239-250.
20. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005; 129:807-818.
21. Vermiere S, et al. Assessment of certolizumab pegol in the treatment of Crohn's disease in patients for whom infliximab treatment was not successful: open-label induction results from the WELCOME Study. In: Congress of European Crohn's and Colitis Organisation; 28 February-1 March 2008; Lyon, France.
22. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126:402-413.
23. Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006; 4:1248-1254.
24. Schnitzler F, Fiddler H, Ferrante M, et al. Long-term outcome of treatment with infliximab in Crohn's disease patients: results of a single center cohort [abstract]. Gastroenterology 2007; 132:A145.
25. Van Assche G, Paintaud G, Magdelaine C, et al. Immunosuppression does not impact on the outcome of maintenance infliximab therapy in Crohn's disease: final results of the IMID trial. Gastroenterology 2007; 132:134.
26. Lichtenstein GR, Diamond RH, Wagner A, et al. Infliximab administered as three dose induction followed by scheduled maintenance therapy in IBD: comparable clinical outcomes with or without concomitant immunomodulators [abstract]. Gastroenterology 2007; 132:A146.
27. Menachem Y, Avidan B, Lavy A, et al. Increasing the infliximab dose is beneficial in Crohn's disease patients who responded to a lower dose and relapsed. Digestion 2005; 72:124-128.
28. Kaplan GG, Hur C, Korzenik J, Sands BE. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Aliment Pharmacol Ther 2007; 26:1509-1520.
29. D'HaensG, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371:660-667.
30. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology 2006; 130:650-656.
31. Bodger K. Economic implications of biological therapies for Crohn's disease: review of infliximab. Pharmacoeconomics 2005; 23:875-888.
32. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003; 348:24-32.
33. Ghosh S. Therapeutic value of alpha-4 integrin blockade in inflammatory bowel disease: the role of natalizumab. Expert Opin Biol Ther 2003; 3:995-1000.
34. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007; 132:1672-1683.
35. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353:1912-1925.
36. Davidson NJ, Hudak SA, Lesley RE, et al. IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. J Immunol 1998; 161:3143-3149.
37. Mannon PJ, Fuss IJ, Mayer L, et al. Antiinterleukin-12 antibody for active Crohn's disease. N Engl J Med 2004; 351:2069-2079.
38. Aggarwal S, Ghilardi N, Xie MH, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003; 278:1910-1914.
39. Shih DQ, Targan SR. Immunopathogenesis of inflammatory bowel disease. World J Gastroenterol 2008; 14:390-400.
40. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314:1461-1463.